Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Betrixaban

FDA-approved product (capsule, oral), marketed as Bevyxxa.

Registered studies
14
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Betrixaban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Recurrent thrombophlebitis
  • Venous thromboembolism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

14registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Betrixaban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Betrixaban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

    NCT04684212 · start 2024-06-01

    Registered record
    Registry ID
    NCT04684212
    Conditions
    Atrial Fibrillation; Left Atrial Appendage Thrombosis; CVA
    Interventions
    LAmbre PlusTM Left Atrial Appendage Closure System; Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2024-06-01
    Completion
    2024-07-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Left Atrial Appendage Thrombosis; CVA
    InterventionLAmbre PlusTM Left Atrial Appendage Closure System; Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
    PhaseNot applicable
    Registry statusWithdrawn

  • Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

    NCT03728166 · start 2019-02-01

    Registered record
    Registry ID
    NCT03728166
    Conditions
    Venous Thromboembolism
    Interventions
    Electronic alert
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2019-02-01
    Completion
    2026-06-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionElectronic alert
    PhaseNot applicable
    Registry statusRecruiting

  • BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

    NCT03613402 · start 2018-09

    Registered record
    Registry ID
    NCT03613402
    Conditions
    Venous Thromboses
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2018-09
    Completion
    2020-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboses
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Study Evaluating Betrixaban in Pediatric Participants

    NCT03346083 · start 2018-07-13

    Registered record
    Registry ID
    NCT03346083
    Conditions
    VTE Prophylaxis
    Interventions
    Betrixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-07-13
    Completion
    2019-10-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVTE Prophylaxis
    InterventionBetrixaban
    PhasePhase 1
    Registry statusTerminated

  • The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

    NCT03397888 · start 2017-11-16

    Registered record
    Registry ID
    NCT03397888
    Conditions
    Hepatic Impairment
    Interventions
    Betrixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-11-16
    Completion
    2018-01-16
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionBetrixaban
    PhasePhase 1
    Registry statusCompleted

  • A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

    NCT02596100 · start 2015-09

    Registered record
    Registry ID
    NCT02596100
    Conditions
    Healthy
    Interventions
    Betrixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-09
    Completion
    2015-11
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBetrixaban
    PhasePhase 1
    Registry statusCompleted

  • A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

    NCT03330457 · start 2015-08-06

    Registered record
    Registry ID
    NCT03330457
    Conditions
    Bleeding
    Interventions
    Andexanet alfa (bolus); Betrixaban 80 mg PO QD; Andexanet alfa (infusion IV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-08-06
    Completion
    2016-02-22
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBleeding
    InterventionAndexanet alfa (bolus); Betrixaban 80 mg PO QD; Andexanet alfa (infusion IV)
    PhasePhase 2
    Registry statusTerminated

  • Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

    NCT01583218 · start 2012-03

    Registered record
    Registry ID
    NCT01583218
    Conditions
    Venous Thromboembolism (VTE)
    Interventions
    Betrixaban; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2016-01
    Enrolment
    7,513

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism (VTE)
    InterventionBetrixaban; Enoxaparin
    PhasePhase 3
    Registry statusCompleted

  • Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

    NCT01229254 · start 2010-09

    Registered record
    Registry ID
    NCT01229254
    Conditions
    Atrial Fibrillation; Atrial Flutter
    Interventions
    Amiodarone; Betrixaban 60 mg; Betrixaban 90 mg; Betrixaban 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-04
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Atrial Flutter
    InterventionAmiodarone; Betrixaban 60 mg; Betrixaban 90 mg; Betrixaban 30 mg
    PhasePhase 2
    Registry statusCompleted

  • A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

    NCT00999336 · start 2009-07-31

    Registered record
    Registry ID
    NCT00999336
    Conditions
    Renal Impairment
    Interventions
    Betrixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07-31
    Completion
    2010-02-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionBetrixaban
    PhasePhase 1
    Registry statusCompleted

  • Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

    NCT00742859 · start 2008-10

    Registered record
    Registry ID
    NCT00742859
    Conditions
    Atrial Fibrillation
    Interventions
    betrixaban; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-11
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventionbetrixaban; Warfarin
    PhasePhase 2
    Registry statusCompleted

  • An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

    NCT01765855 · start 2007-09

    Registered record
    Registry ID
    NCT01765855
    Conditions
    Health Volunteers
    Interventions
    Betrixaban single oral dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-10
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth Volunteers
    InterventionBetrixaban single oral dose
    PhasePhase 1
    Registry statusCompleted

  • A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

    NCT01765868 · start 2007-09

    Registered record
    Registry ID
    NCT01765868
    Conditions
    Healthy Subjects
    Interventions
    Betrixaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionBetrixaban
    PhasePhase 1
    Registry statusCompleted

  • Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

    NCT00375609 · start 2006-05

    Registered record
    Registry ID
    NCT00375609
    Conditions
    Thromboembolism
    Interventions
    Betrixaban; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-02
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    InterventionBetrixaban; Enoxaparin
    PhasePhase 2
    Registry statusCompleted